Key Points
- SVP Paula Green sold 935 shares on March 6 at an average price of $46.43 for about $43,412, leaving her with 124,401 shares (a 0.75% reduction in ownership).
- Twist Bioscience shares were recently down 6.1%; the company reported Q1 EPS of -$0.50 (missed estimates by $0.02) while revenue rose 16.9% year-over-year to $103.7 million, and the stock has a market cap of roughly $2.78 billion.
- Analysts are mixed but generally positive, with seven Buy ratings versus two Sells and an average price target of $45.88, and several firms recently raising targets into the $50–$52 range.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 425 shares of the company's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $46.43, for a total transaction of $19,732.75. Following the transaction, the insider directly owned 138,257 shares in the company, valued at approximately $6,419,272.51. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Dennis Cho also recently made the following trade(s):
- On Wednesday, February 11th, Dennis Cho sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00.
- On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total transaction of $51,191.42.
- On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total transaction of $11,197.44.
Twist Bioscience Price Performance
Shares of NASDAQ:TWST opened at $45.40 on Wednesday. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of -35.47 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The business's 50 day simple moving average is $44.19 and its 200-day simple moving average is $34.92. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $57.88.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm's revenue was up 16.9% compared to the same quarter last year. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC raised its position in shares of Twist Bioscience by 227.6% in the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company's stock valued at $1,328,000 after buying an additional 32,792 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in Twist Bioscience by 14.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company's stock worth $41,171,000 after acquiring an additional 184,726 shares during the period. Baillie Gifford & Co. raised its holdings in Twist Bioscience by 62.8% in the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company's stock valued at $35,533,000 after acquiring an additional 487,052 shares during the last quarter. New York State Common Retirement Fund raised its holdings in Twist Bioscience by 14.0% in the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company's stock valued at $16,453,000 after acquiring an additional 71,777 shares during the last quarter. Finally, William Blair Investment Management LLC lifted its stake in shares of Twist Bioscience by 6.0% during the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company's stock worth $116,564,000 after purchasing an additional 235,679 shares during the period.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on TWST shares. Barclays increased their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an "overweight" rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, February 3rd. Evercore increased their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a research report on Tuesday, February 3rd. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research note on Monday, December 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $45.88.
Get Our Latest Stock Report on Twist Bioscience
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
